Skip to main content

Table 2 The clinical and biochemical data according to PCSK9 levels

From: Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study

Variables

 

PCSK9 (ng/mL)

p

Overall

<  228.48

>  228.48

n = 2293

n = 1146

n = 1147

Clinical data

 Age (years)

55.62 ± 11.01

54.92 ± 11.12

56.32 ± 10.86

0.002

 Male sex n(%)

1387 (60.5)

795 (69.4)

592 (51.6)

< 0.001

 BMI (kg/m2)

25.63 ± 3.38

25.76 ± 3.39

25.49 ± 3.37

0.054

 CAD n(%)

1447 (63.1)

723 (63.1)

724 (63.1)

0.987

 DM n(%)

538 (23.5)

257 (22.4)

281 (24.5)

0.242

 Hypertension n(%)

1418 (61.8)

710 (62.0)

708 (61.7)

0.910

 Smoking n(%)

788 (34.4)

422 (36.8)

366 (31.9)

0.013

 Drinking n(%)

468 (20.4)

261 (22.8)

207

0.005

 Family history of CAD n(%)

514 (22.4)

236 (20.6)

278 (24.2)

0.036

 SBP (mmHg)

128.05 ± 18.01

128.58 ± 17.97

127.52 ± 18.04

0.161

 DBP (mmHg)

79.59 ± 11.19

80.08 ± 11.21

79.1 ± 11.16

0.035

Laboratory parameters

 TC (mmol/L)

4.9 ± 1.09

4.68 ± 0.96

5.12 ± 1.17

< 0.001

 TG (mmol/L)

(1.15,2.3)

1.53 (1.11,2.23)

1.64 (1.19,2.35)

0.012

 HDL-C (mmol/L)

1.11 ± 0.35

1.09 ± 0.36

1.14 ± 0.33

0.001

 LDL-C (mmol/L)

3.2 ± 1

2.99 ± 0.88

3.41 ± 1.08

< 0.001

 Glu (mmol/L)

5.65 ± 1.88

5.6 ± 2.1

5.69 ± 1.64

0.264

 HbA1C (%)

6.02 ± 1.0

5.94 ± 0.94

6.09 ± 1.06

< 0.001

 hsCRP (mg/L)

1.37 (0.72,2.46)

1.32 (0.71,2.46)

1.47 (0.73,2.63)

0.009

Coagulation indexes

 APTT (s)

36.25 ± 3.9

36.46 ± 3.86

36.03 ± 3.92

0.008

 PT (s)

12.75 ± 0.64

12.84 ± 0.63

12.67 ± 0.63

< 0.001

 PT-t (1/s)

0.83 (0.63.1.25)

0.77 (0.59,1.11)

0.83 (0.67,1.43)

< 0.001

 TT (s)

16.4 ± 1.25

16.38 ± 1.08

16.42 ± 1.39

0.386

 Fib (g/L)

3.06 ± 0.73

2.98 ± 0.64

3.15 ± 0.79

< 0.001

 D dimer (μg/mL)

0.31 (0.24,0.41)

0.3 (0.24,0.39)

0.32 (0.24,0.43)

0.011

 Platelet(10^12)

216.79 ± 55.66

211.32 ± 54.48

222.25 ± 56.31

< 0.001

Medication

 Aspirin/Clopidogrel n(%)

748 (32.6)

379 (33.1)

369 (32.2)

0.646

 ACEI/ARB n(%)

383 (16.7)

193 (16.8)

190 (16.6)

0.859

  1. PCSK9 proprotein convertase subtilisin/kexin type 9, BMI body mass index, CAD coronary artery disease, DM diabetes mellitus, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Glu glucose, HbA1C hemoglobin A1C, hs-CRP high-sensitivity C-reactive protein, APTT activated partial thromboplastin time, PT prothrombin time, PT-t transformation of prothrombin time (the inverse of the difference between PT and the minimal PT of normal plasma), TT thrombin time, Fib fibrinogen, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers. p < 0.05 suggested significant difference